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The atria provide an important contribution to cardiac function
[1,2]. Besides their impact on ventricular filling, they serve as a
volume reservoir, host pacemaker cells and important parts of the
cardiac conduction system (e.g. sinus node, AV node), and secrete
natriuretic peptides like atrial natriuretic peptide (ANP) and brain
natriuretic peptide (BNP) that regulate fluid homoeostasis. Atrial
myocardium is affected by many cardiac and non-cardiac condi-
tions [3] and is, in some respects, more sensitive than ventricular
[4]. The atria are activated, besides the three specialised inter-
modal tracts [5,6], through working cardiomyocytes, so that
any architectural or structural change in the atrial myocardium
may cause significant electrophysiological disturbances. In addi-
tion, atrial cells (both cardiomyocytes and non-cardiomyocyte
elements like fibroblasts, endothelial cells, and neurons) react
briskly and extensively to pathological stimuli [3] and are sus-
ceptible to a range of genetic influences [7]. Responses include
atrial cardiomyocyte hypertrophy and contractile dysfunction,
arrhythmogenic changes in cardiomyocyte ion-channel and
transporter function, atrial fibroblast proliferation, hyperinnerva-
tion, and thrombogenic changes [2]. Thus, atrial pathologies have a
substantial impact on cardiac performance, arrhythmia occur-
rence, and stroke risk [1,8].
Ventricular cardiomyopathies have been well classified;
however, a definition and detailed analysis of ‘atrial cardiomyo-
pathy’ is lacking from the literature. The purpose of the present
consensus report, prepared by a working group with repre-
sentation from the European Heart Rhythm Association (EHRA),
the Heart Rhythm Society (HRS), the Asian Pacific Heart Rhythm
Society (APHRS), and Sociedad Latino Americana de Estimulacion
Cardiaca y Electrofisiologia (SOLAECE), was to define atrial car-
diomyopathy, to review the relevant literature, and to consider
the impact of atrial cardiomyopathies on arrhythmia manage-
ment and stroke.
1.1. Definition of atrial cardiomyopathy
The working group proposes the following working definition
of atrial cardiomyopathy: ‘Any complex of structural, architectural,
contractile or electrophysiological changes affecting the atria with
the potential to produce clinically-relevant manifestations’
(Table 1).
Many diseases (like hypertension, heart failure, diabetes, and
myocarditis) or conditions (like ageing and endocrine abnormal-
ities) are known to induce or contribute to an atrial cardiomyo-
pathy. However, the induced changes are not necessarily disease-
specific and pathological changes often share many similarities
[9,10]. The extent of pathological changes may vary over time and
atrial location, causing substantial intraindividual and inter-
individual differences. In addition, while some pathological pro-
cesses may affect the atria very selectively (e.g. atrial fibrillation-
induced remodelling), most cardiomyopathies that affect the atria
also involve the ventricles to a greater or lesser extent. There is no
presently accepted histopathological classification of atrial
pathologies. Therefore, we have proposed here a workingTable 1
Definition of atrial cardiomyopathy.
‘Any complex of structural, architectural, contractile or electrophysiological
changes affecting the atria with the potential to produce clinically-relevant
manifestations’.histological/ pathopysiological classification scheme for atrial car-
diomyopathies (Table 1; Fig. 1). We use the acronym EHRAS (for
EHRA/HRS/ APHRS/SOLAECE), defining four classes: (I) principal
cardiomyocyte changes [11–15]; (II) principally fibrotic changes
[10,14,16]; (III) combined cardiomyocyte-pathology/fibrosis
[9,11,12]; (IV) primarily non-collagen infiltration (with or without
cardiomyocyte changes) [17–19]. This simple classification may
help to convey the primary underlying pathology in various clin-
ical conditions. The EHRAS class may vary over time and may
differ at atrial sites in certain patients. Thus, this classification is
purely descriptive and in contrast to other classifications (NYHA
class, CCS class etc.), there is no progression in severity from
EHRAS class I to EHRAS IV (Table 2). The classification may be
useful to describe pathological changes in biopsies and to correlate
pathologies with results obtained from imaging technologies etc.
In the future, this may help to define a tailored therapeutic
approach in atrial fibrillation (AF) (Figs. 1–3).2. Anatomical considerations and atrial muscular architecture
2.1. Normal atrial structures
2.1.1. Gross morphology
Each atrium has a morphologically characteristic atrial body
and appendage (Fig. 4). In the body, there is a venous component
with the orifices of the systemic or pulmonary veins (PVs) and a
vestibular component that surrounds the atrial outlet [20]. The
interatrial septum (IAS) separates the atrial bodies. The venous
component of the left atrium (LA) is located posterosuperiorly
and receives the PVs at the four corners, forming a prominent
atrial dome. The LA is situated more posteriorly and superiorly
than the right atrium separated by the obliquity of the plane of
the IAS [21].
The LA appendage (LAA) is smaller than the right atrium
appendage (RAA). Narrower and with different shapes has a
distinct opening to the atrial body and overlies the left circum-
flex coronary artery. Its endocardial aspect is lined by a com-
plex network of muscular ridges and mem-branes [22,23].
Different LAA morphologies have been described, and it appears
that LAA morphology correlates with the risk of thrombogenesis
[24].
Bachmann's bundle is a broad epicardial muscular band run-
ning along the anterior wall of both atria (Fig. 4). The rightward
arms extend superiorly towards the sinus node and inferiorly
towards the right atrioventricular groove, while the leftward arms
blend with deeper myofibres to pass around the neck of the LAA
and reunite posteriorly to join the circumferential vestibule of the
LA. The walls of LA are non-uniform in thickness (1–15 mm) and
thicker than the right atrium [25].
2.2. Normal atrial myocardium
2.2.1. Atrial cardiomyocytes
Atrial cardiomyocytes are geometrically complex cylinders that
sometimes bifurcate at their ends where they connect with adja-
cent fibres via band-like ‘intercalated discs’. This contractile syn-
cytium is organised in well-defined bands that establish non-
uniform anisotropic propagation of the atrial impulse [9,11,26].
The only clear light-microscopic morphological difference
between atrial and ventricular cardiomyocytes is in size [27]. In
paraffin-embedded human specimens, the cardiomyocyte trans-
verse diameter is 12 mm in the LAs vs. 20–22 mm in the ven-
tricles [11,28]. Atrial cardiomyocytes are mainly mononucleated; a
Fig. 1. Histological and pathopysiological classification of atrial cardiomyopathies (EHRA/HRS/APHRS/SOLAECE): EHRAS classification. The EHRAS class may vary over time in
the cause of the disease and may differ at various atrial sites. Of note, the nature of the classification is purely descriptive. EHRAS I–IV is not intended to describe disease
progression from EHRAS I to EHRAS IV.
Table 2
EHRAS classification of atrial cardiomyopathy.
EHRAS class Histological characterisation
I [11–15,503] Morphological or molecular changes affecting ‘primarily’
the cardiomyocytes in terms of cell hypertrophy and
myocytolysis; no significant pathological tissue fibrosis
or other interstitial changes
II [8,12,14,504–506] Predominantly fibrotic changes; cardiomyocytes show
normal appearance
III [9,11,12,217,266] Combination of cardiomyocyte changes (e.g. cell hyper-
trophy, myocytolysis) and fibrotic changes Alteration of
interstitial matrix without prominent
IV [17–19] collagen fibre accumulation
Iva Accumulation of amyloid
IVf Fatty infiltration
IVi Inflammatory cells
IVo Other interstitial alterations
A. Goette et al. / Journal of Arrhythmia 32 (2016) 247–278250minor fraction possess two or more nuclei. The nucleus is usually
centrally located, with granular and/or condensed chromatin. The
nuclear shape is influenced by fibre contraction, becoming more
fusiform with longitudinal cell stretch [29]. Biochemically, atrial
cardiomyocytes have greater lipid content than ventricular muscle
cells [30].
Atrial cardiomyocytes share many characteristics with ven-
tricular in terms of nucleus, contractile apparatus, cytoskeleton,
and organelles [27,29,31,32]. Unlike ventricular cardiomyocytes,
atrial cardiomyocytes do not possess an extensive T-tubule net-
work but they do have prominent sarcoplasmic reticulum (SR)
elements known as Z-tubules [33]. Therefore, the atrial sarco-
lemma does not protrude into the cell, and voltage-operated Ca2þ
channels mainly function at the cell periphery [34]. Atrialcardiomyocytes display specific granules (100–400 nm) situated
mainly in the paranuclear area adjacent to the Golgi apparatus,
which contain ANP, the BNP, and related peptides [23,24].
2.2.2. Atrial interstitium
Atrial interstitium consists of cellular and extracellular com-
ponents (see Figs. 2–5). The cellular elements include fibroblast/
myofibroblasts, adipocytes, undifferentiated mesenchymal cells,
and isolated inflammatory cells. The atrial wall has a significant
number of medium-sized blood vessels, especially in the sub-
epicardium. Mature adipose tissue is frequently found in atrial
myocardium, especially the epicardium, and often permeates the
layers around intramural coronary branches. The number of adi-
pocytes is highly variable and increases with age [27]. The extra-
cellular components consist of collagen fibres, which form most of
the myocardial skeleton, proteoglycan particles, lipidic debris,
spherical micro-particles, and matrix vesicles [27].
Collagen fibres, mainly type I, are both normal and essential
components (Figs. 1–5). Atrial fibrous tissue may be sub-divided
into pure interstitial and perivascular (or adventitial). Interstitial
collagen fibres represent 5% of the atrial wall volume. The atrial
myocardium is also the site of sparse postganglionic nerve endings
(from the ‘intrinsic cardiac nervous system’), mostly within dis-
crete fat pads but also among cardiomyocytes [35].3. Atrial-specific physiological and functional considerations
3.1. Atrial-selective electrophysiological properties
The atria have a number of electrophysiological features that
distinguish them from the ventricles and govern their arrhythmia
susceptibility.
Fig. 2. (A) EHRAS Class I (biopsy): there are severe changes affecting ‘primarily’ the cardiomyocytes in terms of cell hypertrophy and myocytolysis; fibrosis is much less
evident than myocyte modifications. (B) EHRAS Class II (biopsy): cardiomyocyte alterations are relatively modest compared with severe fibrotic changes; in this case,
interstitial changes are much more prevalent than myocyte ones. (C) EHRAS Class III (biopsy): this is a combination of cardiomyocyte changes and collagen fibre deposition.
(D) EHRAS Class IV (autopsy heart): primarily neutro-philic myocarditis.
Fig. 3. EHRAS Class IV (autopsy heart): this image shows a myocardial interstitial
with some fibrosis but prominent amyloid (AL type) deposition (left-hand side,
congo red staining under regular light microscope; right-hand side, congo red
staining under polarised light microscope).
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Atrial cardiomyocytes have distinct action potential (AP)
properties from ventricular cardiomyocytes, resulting in a large
part from distinct ion-channel properties and distribution
(Fig. 6A) [36,37]. Atrial background inward-rectifier Kþ current
(IK1) is smaller than that of ventricular Kþ current, resulting in a
less negative resting potential and more gradual slope of phase-3
repolarization. Atrial cells also have two Kþ-currents that are
absent in ventricle cells: the ultrarapid delayed rectifier current
(IKur) and the acetylcholine-regulated Kþ-current (IKACh).
In addition, there is evidence that atrial Naþ-current has dif-
ferent properties compared with ventricular current [38]. As
well as distinctions between atrial and ventricular APs, different
atrial regions may have discrete AP and ion-channel properties
[37,39]. These cellular electrophysiological characteristics have
implications for antiarrhythmic drug action and design, and
may also affect the responses to atrial arrhythmias and disease
[36,37].
3.3. Intercellular coupling properties
The atria have a different pattern of cell-to-cell coupling pro-
tein (connexin) distribution compared with ventricular myo-
cardium [36]. Whereas working ventricular cardiomyocytes
express connexin-43 exclusively, atrial cardiomyocytes have sig-
nificant expression of connexin-40 (Fig. 6B) [36]. Heterogeneitiesin connexin-40 distribution are common in paroxysmal AF and
may play a pathophysiological role [40], and gene variants
affecting connexin-40 sequence and/or transcription predispose to
AF occurrence [41].
Fig. 4. Schematic representations and heart dissections to show the arrangement of the myocardial strands in the superficial parts of the walls. (A) The dissection viewed
from the anterior aspect display the interatrial muscle Bachmann bundle and its bifurcating branches leftward and rightward. (B) A view of the roof and posterior wall of the
left and right atriums. The right pulmonary veins (PVs) passes behind the intercaval area. The subepicardial dissection shows the abrupt changes in fibre orientation and the
myocardial strands (septopulmonary bundle) in the region between the left and right PVs. The red arrows show multiple muscle bridges connecting the two atria. ICV,
inferior caval vein; LAA, left atrial appendage; LSPV, left superior pulmonary vein; MV, mitral valve; RAA, right atrial appendage; RIPV, right inferior pulmonary vein; RSPV,
right superior pulmonary vein; SCV, superior caval vein; TV, tricuspid valve (see text for details).
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The atria have a very complex 3D structure (Fig. 6C) not found
in the ventricles. These include interatrial connections limited to
Bachmann's bundle, the septum, and the CS; pectinate muscles,
the crista terminalis, and fibres surrounding the coronary sinus in
the right atrium; and the PVs with complex fibre orientation
around them in the LA. These structural complexities have
important potential implications for atrial patho-physiology and
management of atrial arrhythmias [42]. Extensive recent work has
gone into the realistic mathematical reconstruction of such geo-
metric complexities [43], and they have been incorporated into
analytical approaches designed to implement patient-specific
arrhythmia therapies [44]. Cable-like strands of atrial tissue like
the pectinate muscles and crista terminalis are organised such that
conduction within them is primarily longitudinal, with an ‘aniso-
tropy ratio’ (longitudinal/transverse conduction velocities) as greatFig. 5. Normal histology of the left atrium and relevant pathological changes in mitral v
atrial myocardium which is composed of large bands of homogeneous cardiomyocytes.
(red colour) are primarily seen in the adventitial spaces of blood vessels (arrow). (C) Lo
atrial fibrillation. Large bands of cardiomyocytes are separated by significant amounts of
staining shows that the pathologic fibrous significantly thickens the perivascular spaces (
(interstitial fibrosis, arrowhead). (E) In atrial fibrillation, a variable number of cardiomy
resulting in so-called myocytolysis. These spaces may be empty (arrow) or filled with glyc
(arrow) and optically empty (arrowhead) cardiomyocytes. (G) Ultrastructural view of a
nucleus (asterisk). In this empty area, there is very often accumulation of mitochondria
(arrow). (H) An LA from a patient with atrial fibrillation where the myocardial microcir
haematoxylin–eosin staining; (B and D) Van Gieson staining for collagen; (E and F) Period
with an anti-CD31 antibody. Original magnifications. (A, B, E, and H) 20; (C and D) as 10, whereas in working ventricular muscle the ratio is typically
more between 2 and 4 [45].3.5. Autonomic ganglia
There are autonomic ganglia on the surface of the heart that are
important way-stations for cardiac autonomic control [46].
Moreover, alterations in local cardiac innervation and intracardiac
autonomic reflexes play an important role in physiology and
arrhythmia control. Most of the cardiac autonomic ganglia are
located on the atria, and in particular in the region of the PV ostia.
Thus, they are well positioned to affect atrial electrical activity in
regions particularly important in AF, and their alteration by ther-
apeutic manoeuvers like PV ablation may contribute to antiar-
rhythmic efficacy [42,46,47].alve disease-associated atrial fibrillation. (A) Medium-power view of a normal left
(B) In the same atrium as in (A), the Van Gieson staining show that collagen fibres
w-power view of a left atrium from a patient with mitral valve disease-associated
pathologic fibrous tissue (arrows). (D) In the same atrium as in (C), the Van Gieson
perivascular fibrosis, arrow) and separates single or small groups of cardiomyocytes
ocytes undergo loss of contractile elements starting from the perinuclear area and
ogen (arrowhead). (F) A higher-power view of myocytolysis with both glycogen rich
myolytic cardiomyocyte with significant loss of contractile elements around the
(arrowhead) while the adjacent myofibrils display signs of abnormal contraction
culation (arrow) is slightly reduced and irregularly distributed. Stainings. (A and C)
ic acid Schiff staining; (G) ultrastructural image; (H) immunohistochemical analysis
4; (F) 40; (G) 2800.
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The left atrial contribution to overall cardiovascular perfor-
mance is determined by unique factors. First, left atrial function
critically determines left ventricular (LV) filling. Second, chamber-
specific structural, electrical and ion remodelling alter left atrial
function and arrhythmia susceptibility. Third, atrial function is
highly relevant for the therapeutic responses of AF. Fourth, LA
volume is an important biomarker that integrates the magnitude
and duration of LV diastolic dysfunction. The development of
sophisticated, non-invasive indices of LA size, and function might
help to clinically exploit the importance of LA function in prog-
nosis and risk stratification [1,48].
Fibre orientation of the two thin muscular layers (the fas-
cicles of which both originate and terminate at the atrioven-
tricular ring) introduce a complexity that challenges functional
analysis. Ultrastructurally, atrial cardiomyocytes are smaller in
diameter, have fewer T-tubules, and more abundant Golgi
apparatus than ventricular. In addition, rates of contraction and
relaxation, conduction velocity, and anisotropy differ, as does
the myosin isoform composition and the expression of ion
transporters, channels, and gap junctional proteins (see relevant
sections).
3.7. Functions of the left atrium
The principal role of the LA is to modulate LV filling and car-
diovascular performance by operating as a reservoir for PV return
during LV systole, a conduit for PV return during early LV diastole,
and as a booster pump that augments LV filling during LV diastole.
There is a critical interplay between these atrial functions and
ventricular systolic and diastolic performance. Thus, while LA
compliance (or its inverse, stiffness), and, to a lesser extent, LA
contractility and relaxation are the major determinants of reser-
voir function during LV systole, LV end-systolic volume and des-
cent of the LV base during systole are important contributors.
Conduit function is also governed by LA compliance and is reci-
procally related to reservoir function, but because the mitral valve
is open in diastole, conduit function is also closely related to LV
compliance (of which relaxation is a major determinant). Atrial
booster-pump function reflects the magnitude and timing of atrial
contractility, but also depends on venous return (atrial preload), LV
end-diastolic pressures (atrial afterload), and LV systolic reserve.
3.7.1. Left atrium booster-pump function
Left atrium booster-pump function represents the augmented
LV-filling resulting from active atrial contraction (minus retro-
grade blood-ejection into the PVs) and has been estimated by
measurements of (i) cardiac output with and without effective
atrial systole, (ii) relative LV-filling using spectral Doppler of
transmitral, PV, and LA-appendage flow, (iii) LA-shortening and
volumetric analysis, and (iv) tissue Doppler and deformation
analysis (strain and strain-rate imaging) of the LA-body [1].
Booster-pump function can also be evaluated echocardio-
graphically by estimating the kinetic energy and force generated
by LA contraction. The relative importance of the LA contribution
to LV filling and cardiac output remain controversial. A load-
independent index of LA contraction based on the analysis of
instantaneous relation between LA pressure and volume, analo-
gous to LV end-systolic elastance measurements, has been used as
a load-independent measure of LA pump function, validated
ex vivo and in the intact dog (Fig. 7) [49]. While LA pressure–
volume loops can be generated with invasive and semi-invasive
means in humans [50], these methods are cumbersome, time-
consuming, and difficult to apply. Measurement of myocardial
strain and strain rate, which represent the magnitude and rate ofmyocardial deformation, assessed using either tissue Doppler
velocities (tissue Doppler imaging, TDI) or by 2D echocardio-
graphic (2D speckle-tracking or STE) techniques (Fig. 8) provide
objective, non-invasive measurements of LA myocardial perfor-
mance and contractility that overcome these limitations [1,51].
3.7.2. Left atrium reservoir function
Nearly half of the LV stroke volume and its associated energy
are stored in the LA during LV systole. This energy is subsequently
expended during the LV diastole. Reservoir function is governed
largely by atrial compliance during ventricular systole, which is
measured most rigorously by fitting atrial pressures and dimen-
sions, taken either at the time of mitral valve opening/closure over
a range of atrial pressures and volumes or during ventricular
diastole, to an exponential equation [52]. Although this method
requires atrial dimensions and pressures, the relative reservoir
function can be estimated simply with PV Doppler: the proportion
of LA inflow during ventricular systole provides an index of the
reservoir capacity of the atrium. Reservoir function can also be
estimated from LA time–volume relations as either the total
ejection fraction or distensibility fraction, calculated as the max-
imum minus minimum LA volume, normalised to maximal or
minimal LA volume, respectively.
Although largely neglected, the LA–appendage is more com-
pliant than the LA–body [52], so the contribution of the appendage
to overall LA compliance is substantial with potential negative
implications for routine atrial appendectomy/ligation during
mitral valve surgery.
Left atrium strain and strain rates during LV systole predict
successful sinus rhythm restoration following DC cardioversion or
AF ablation, and are surrogates of atrial fibrosis and structural
remodelling; coupled with an estimate of atrial pressure (e.g.
transmitral E/E0), strain has the potential to estimate atrial dis-
tensibility non-invasively [1,53].
3.7.3. Left atrium conduit function
Left atrium conduit function occurs primarily during ven-
tricular diastole and represents the trasport of blood volume that
cannot be attributed to either reservoir or booster-pump func-
tions, accounting for approximately one-third of atrial flow [54]. A
reciprocal relation exists between LA conduit and reservoir func-
tions; a redistribution between these functions is an important
compensatory mechanism that facilitates LV filling with myo-
cardial ischaemia, hypertensive heart disease, and mitral stenosis
(MS). Conduit function is estimated by the early diastolic trans-
mitral flow, diastolic PV-flow, and LA strain and strain rate during
early diastole.
3.8. Atrial-selective Ca [21] handling
There are major differences in the expression and function of
Ca2þ-handling proteins between atria and ventricles (Fig. 9) [55].
The atria have reduced cardiomyocyte contraction and relaxation
times and shorter Ca2þ-transient duration [56–58]. In atria, pro-
tein levels [57,59] and activity [57,59] of the SR Ca2þ-ATPase2a
(Serca2a) are two-fold higher, whereas the Serca2a-inhibitor
phospholamban (PLB) is less abundant, vs. ventricles [57,59].
Atrial, but not ventricular, Serca2a is also regulated by sarcolipin
(SLN) and SLN ablation increases atrial SR Ca2þ-uptake and con-
tractility [60]. L-type Ca2þ-current [61] is similar in both cham-
bers, whereas protein levels of ryanodine receptor type-2, calse-
questrin, triadin, junction and Na2þ –Ca2þ exchanger are lower in
atria than in ventricles [59,62,63]. In contrast to ventricular myo-
cardium, T-tubules are less abundant in atrial cardiomyocytes [64].
In addition, atrial cardiomyocytes possess much more Ca2þ-buf-
fering mitochondria than ventricular cardiomyocytes [56]. As a
Fig. 6. (A) Comparison of atrial and ventricular action potential properties and underlying ionic currents. Resting potentials (2 mV) are more negative (averaging 280–
285 mV) in ventricular vs. atrial (270–275 mV) myocytes. (B) Connexin distribution differs between atria and ventricles, with connexin-43 only expressed in ventricular
cardiomyocytes (CMs) but atrial CMs having both connexin-40 and connexin-43. (C) Ralistic reconstruction of the structure of sheep atria. The right atrium (RA), left atrium
(LA), pectinate muscles (PM), Bachmann's bundle (BB) and pulmonary veins (PV) are colour coded. From Ref. [43] with permission.
Fig. 7. Left atrial pressure–volume loop. (A) Analogue recordings of left atrial pressure and dimensions in the time domain. Vertical lines indicate time of mitral valve
opening (A), end of passive atrial emptying and onset of atrial diastasis (B), atrial end-diastole (C), and atrial end-systole (D). a and v represent respective venous pressure
waves. (B) Left atrial pressure–volume loop from a single beat illustrating characteristic figure-of-eight configuration. Arrows indicate the direction of loop as a function of
time. A loop represents active atrial contraction. V loop represents passive filling and emptying of the LA. MVO, time of mitral valve opening; MVC, approximate time of
mitral valve closure; LA, left atrial end-systole; and LAd, left atrial end-diastole. Reproduced from Ref. [49] with permission.
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Fig. 8. LA functions colour-coded displays of atrial functions (red, reservoir; blue, conduit; yellow, booster pump) related to events in the cardiac cycle. Displayed are
pulmonary venous (PV) velocity, LA strain, LA strain rate, LA volume and pressure, and mitral spectral and tissue Doppler. Reproduced from Ref. [1] with permission.
A. Goette et al. / Journal of Arrhythmia 32 (2016) 247–278256consequence, the atrial Ca2þ wave starts in the myocyte periphery
and then propagates to the centre of the myocyte, activating
additional Ca2þ-releasing sites in the SR [55].4. Pathology of atrial cardiomyopathies
4.1. Lone atrial fibrillation (atrial fibrillation without concomitant
conditions)
‘Lone’ atrial fibrillation (LAF) is diagnosed when no apparent
explanation or underlying comorbidity can be identified [65,66].
Over the last few years, new epidemiological associations with AF
have emerged and the number of true LAF cases has progressively
decreased [67]. Like AF associated with comorbidities, LAF occurs
more frequently in males than in females with a ratio of 3–4:1
[68]. Recent studies have shown that true cases of LAF can be
diagnosed even in subjects older than 60 years, so that this age
limit seems inappropriately conservative [69]. At the same time, it
is unclear whether cases with left atrial enlargement should be
excluded from the LAF category. In fact, LA enlargement might
even be the consequence of the arrhythmia [70].‘Lone’ atrial fibrillation is at the lower end of the thromboem-
bolic risk spectrum, with only a 1–2% cumulative 15-year risk of
stroke [66]. How-ever, with ageing and/or the occurrence of car-
diovascular comorbidities, the risk of AF-related complications
(including thromboembolic events) increases [71]. Patients ori-
ginally diagnosed with LAF may follow different clinical courses
based on their left atrial volume: individuals who retain normal LA
size throughout long-term follow-up show a relatively benign
course, while those with LA enlargement experience adverse
events like stroke, myocardial infarction, and heart failure [72].
The majority of LAF patients first present with paroxysmal epi-
sodes and show low progression rates into permanent AF [71,73].
Atrial fibrillation has clear genetic determinants [7]. These
include common gene variants with low predictive strength and
rare gene mutations that have much greater penetrance [7].
Frustaci et al [14]. explored the histological morphology of right
atrial septal biopsies from patients with lone paroxysmal AF,
finding chronic inflammatory infiltrates, foci of myocyte necrosis,
focal replacement fibrosis, and myocyte cytoplasmic vacuoles
consistent with myolysis. Of their 12 patients, 10 showed EHRAS
class III changes and 2 showed EHRAS class II. Stiles et al [74].
found bi-atrial structural change, conduction abnormalities, and
Fig. 9. Excitation–contraction coupling in atria vs. ventricles. Schematic representation of the cell structure and major Ca2þ handling proteins, along with related currents
and ion transporters (A). Illustration of action potential (top), Ca2þ transient (middle) and confocal linescan image of intracellular Ca2þ wave propagation towards cell centre
(bottom) in a ventricular (left) vs. atrial (right) cardiomyocyte (B). Arrows indicate differences in expression and/or function of Ca2þ handling proteins in atrial vs. ventricular
cardiomyocytes. INa, Naþ current; FKPB12.6, FK506-binding protein 12.6; JPH2, Junctophilin-2; MyBP-CMyosin bindig protein C; TnI, Troponin-I; for further abbreviations,
see text.
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[75]. demonstrated atrial perfusion abnormalities and coronary
flow reserve impairment. Much more recently, morphometric
assessment of atrial biopsies from the LA posterior wall of per-
sistent or long-lasting persistent LAF patients demonstrated car-
diomyocyte hypertrophy, myolytic damage, interstitial fibrosis,
and reduced connexin-43 expression vs. controls [76].
4.2. Isolated atrial amyloidosis
The accumulation of insoluble, misfolded proteins is linked to
an increasing number of age-related degenerative diseases [77].
Amyloidosis represent the deposition of insoluble, fibrillar pro-
teins in a cross b-sheet structure that characteristically binds dyes
such as Congo red. The most common form of age-related or senile
amyloidosis is limited to the atrium, a condition known as isolated
atrial amyloidosis (IAA) [17,78]. The incidence of atrial amyloidosis
increases with age, exceeding 90% in the ninth decade [79].Isolated atrial amyloidosis is also linked to structural heart disease.
In atrial biopsies from 167 patients undergoing cardiac surgery, 23
of 26 amyloid-positive specimens were from patients with rheu-
matic heart disease (RHD), while the remaining 3 came from
patients with atrial septal defects [80]. The overall incidence of
16% was greater than that was seen in control atrial autopsy spe-
cimens from trauma victims (3%). Histologically, IAA is classified as
EHRAS IVa (Fig. 3; Table 2). Atrial natriuretic peptide is a fibrillo-
genic protein that forms IAA [81]. Amyloid deposits are immu-
noreactive for ANP in most patients [17], while transthyretin, a
transport protein implicated in systemic senile amyloidosis, was
also identified in 10% [4] (NT-pro-ANP has been identified in other
studies [82]). As with fibrosis, amyloidosis can cause local con-
duction block and P-wave duration is increased in IAA. Atrial
amyloid is found more commonly in patients with AF vs. sinus
rhythm (Fig. 3). Both AF and IAA increased with advancing age and
female sex, but the relationship between the two is independent
of age and gender [83,84]. Isolated atrial amyloidosis is detected in
Table 3
Hereditary muscular dystrophies with cardiac involvement.
Muscular dystrophy Protein/gene Primary cardiac disease
Duchenne dystrophin DCM
Becker dystrophin DCM
Myotonic dystrophy, type 1 DMPK CSD
Emery-Dreifuss Emerin CSD
Lamin A/C (DCM)
Limb-Girdle Lamin A/C CSD
Sarcoglycans CM
others
Facioscapulohumeral Dux 4 CSD (rare)
DCM, dilated cardiomyopathy; CSD, conduction system disease; DMPK, myotonic
dystrophy protein kinase.
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amyloidosis such as Alzheimer's disease, there is no detectable
correlation between quantity of fibrillar deposits and disease
advancement [85]. Rather, disease phenotype correlates most
closely with accumulation of soluble, prefibrillar protein aggre-
gates [86]. Preamyloid oligomers (PAOs) are cytotoxic to cardio-
myocytes [87]. They do not bind Congo red and thus are not visible
by standard amyloid staining methods. Using a conformation-
specific antibody, PAOs often co-localising with ANP were detected
in atrial samples of 74 of 92 patients without AF undergoing car-
diac surgery [88]. The preamyloid oligomer content was inde-
pendently associated with hypertension. Additional studies are
needed to further confirm this association and whether PAOs are
increased in AF.
4.3. NPPA mutations
Atrial natriuretic peptide is released from the atria in response
to atrial stretch or volume expansion, and produces natriuresis,
diuresis, and vasodilation [89]. It also interacts with other endo-
genous systems, inhibiting the renin–angiotensin-II–aldosterone
and sympathetic nervous systems, and regulates ion currents
[90,91]. Atrial natriuretic peptide-knockout mice develop cardiac
hypertrophy and exaggerated responses to hypertrophic stress
[92]. The gene encoding the precursor protein for ANP, NPPA,
encodes prepro-ANP, a 151 amino acid protein that includes a
signal peptide cleaved off to form pro-ANP [93], which is stored in
dense granules in the atria. Released pro-ANP undergoes proteo-
lytic processing to generate N-terminal pro-ANP and ANP, 98 and
28 amino acids in length, respectively. N-terminal pro-ANP is
cleaved into three hormones with biological activity similar to
ANP: long-acting natriuretic hormone (LANH), vessel dilator pep-
tide, and kaliuretic hormone.
Genetic studies have linked abnormal ANP production to
familial atrial tachyrrhythmias and atrial cardiomyopathy. In a
large family with Holt–Oram syndrome, a missense mutation in T-
box transcription factor 5 (TBx5) resulted in an atypical phenotype
with early-onset AF and the overexpression of multiple genes,
including NPPA [94]. In a large family with multiple members
having early-onset LAF, a 2-bp deletion was identified that abol-
ishes the ANP stop codon, producing a mature protein containing
the usual 28 amino acids plus an anomalous C-terminus of 12
additional residues [95]. The mutant ANP peptide is present in
affected family members at plasma concentrations 5–10 times
higher than wild-type ANP. Studies of the electrophysiological
effects of ANP have been inconsistent [96].
Additional NPPA variants (S64R and A117V) have also been
linked to AF [97,98]. The S64R variant occurs in vessel dilator
peptide rather than ANP. A truncated peptide containing this
mutation increased IKs several fold, an effect predicted to shorten
action potential duration (APD) [97], but the variant has also been
identified in unaffected elderly individuals without AF [96], and its
functional pathological significance remains uncertain.
More recently, an autosomal-recessive atrial cardiomyopathy
was described in patients harbouring an NPPA mutation
(Arg150Gln) predicted to be damaging to protein structure [99].
The phenotype is characterised by biatrial enlargement, initially
associated with atrial tachyarrhythmias such as AF and atrial
flutter [100]. Biatrial enlargement progresses to partial and ulti-
mately severe atrial standstill, associated with progressive
decreases in atrial voltage and extensive atrial scarring. Whether
atrial structural changes are primary, or secondary to atrial
enlargement, is unknown. Loss of the antihypertrophic effects of
ANP may cause the massive atrial enlargement seen in these
patients.4.4. Hereditary muscular dystrophies
A common finding in many inherited muscular dystrophies is
cardiac involvement, related to myocyte degeneration with fatty or
fibrotic replacement (Table 3) [101–103]. In some cases, this can be
the presenting or predominant clinical manifestation. Multiple
complexes and pathways are involved in the maintenance of
myocyte integrity, and a defective or absent protein component
can lead to progressive cell death. The large dystrophin–glyco-
protein complex links the myocyte cytoskeleton to the extra-
cellular basement membrane. For diseases of dystrophin, sarco-
glycans, and other complex-related proteins, the most prominent
manifestation is a dilated cardiomyopathy due to diffuse myocyte
involvement, with arrhythmias and conduction abnormalities
secondary to LV dysfunction [101–105]. Specific atrial involvement
can lead to sinus node disease and/or atrial arrhythmias with
associated thromboembolic events [106,107]. Myotonic dystrophy
type I is the most common muscular dystrophy presenting in
adults [108]. Up to 15% develop atrial arrhythmias during a 10-year
follow-up [109]. The presence of conduction defects and atrial
arrhythmias are independent risk factors for sudden death
[103,110]. In Emery-Dreifuss and Limb-Girdle type IB disease,
widespread atrial fibrosis can lead to atrial standstill [101]. In
Emery-Dreifuss, AF and atrial flutter with slow ventricular
responses and asystolic pauses can be observed, coupled with the
occurrence of thromboembolism and stroke [111]. In facioscapu-
lohumeral muscular dystrophy, arrhythmias are rare, with the
most common being supraventricular tachycardia [112]. Histolo-
gically, the tissue composition may vary substantially, including all
EHRAS classes (see Table 2).
4.5. Atrial cardiomyopathy due to congestive heart failure
Congestive heart failure (CHF) is a common cause (contributing
condition) of AF [3]. The CHF-induced atrial phenotype is complex.
A particularly important component is atrial fibrosis, which in
experimental models occurs earlier in the course of CHF, and to a
much greater extent, than in the ventricles, at least in part because
of atrial-ventricular fibroblast–phenotype differences [4]. Con-
gestive heart failure-related fibrosis slowly, if at all, and the AF-
promoting substrate predominantly tracks fibrosis rather than
other components of atrial remodelling like ion-current or con-
nexin changes. Unlike the case for AF-induced remodelling, the
atrial ion-current changes in CHF do not abbreviate APD or cause
overall conduction slowing [113,114], so they do not contribute
directly to arrhythmogenesis. On the other hand, CHF atria are
prone to triggered activity due to abnormal Ca2þ handling [115].
The principle underlying abnormality appears to be increased
cellular Ca2þ load. While the underlying mechanisms are not
completely clear, they likely include phospholamban
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prolongation (which increases Ca2þ loading by enhancing the
period during which L-type Ca2þ channels are open). The final
phenotypic product of the CHF-induced Ca2þ-handling abnorm-
alities is focal ectopic activity due to aberrant diastolic Ca2þ-
release events from the SR, similar to abnormalities seen with
paroxysmal and long-standing persistent AF [116].
Congestive heart failure also causes atrial hypocontractility,
despite increased cytosolic Ca2þ transient, indicating reduced
contractile sensitivity to intracellular Ca2þ , possibly because of
reduced expression of total and phosphorylated myosin-binding
protein C [115]. This hypocon-tractility may be important in con-
tributing to the increased likelihood of thromboembolic events in
AF patients who also have CHF. Of the atrial changes that occur in
CHF, many are also seen in the ventricle. However, the highly
atrial-selective fibrosis may contribute to atrial cardiomyopathy in
the absence of clear signs of disturbed ventricular function, par-
ticularly in patients with prior CHF events who later become well-
compensated under therapy or after resolution of the underlying
cause. Collagen depositions are prominent in CHF, leading most
commonly to EHRAS Class II and III properties. However, EHRAS
Class IVi and IVf may also be found in certain areas of the atria (see
Table 2).
4.6. Obstructive sleep apnoea
Obstructive sleep apnoea (OSA) is known to impair cardiac
function and predispose to AF [117–119]. Obstructive sleep apnoea
prolongs atrial conduction times, slows atrial conduction, reduces
atrial-electrogram voltages and increases electrogram complexity
[117,118]. Signal-averaged P-wave duration is increased by OSA,
and decreases significantly with continuous positive airway pres-
sure treatment [120]. In a rat model, repeated obstructive apnoea
over a 4-week period increases AF vulnerability and slows atrial
conduction by altering connexin-43 expression and inducing atrial
fibrosis [121].
4.7. Atrial fibrillation-induced atrial remodelling
Atrial fibrillation itself induces atrial remodelling that con-
tributes to the maintenance, progression, and stabilisation of AF
[41,116]. The high atrial rate causes cellular Ca2þ loading. This
induces a decrease in ICa,L due to down-regulation of the under-
lying Cav1.2 subunits, and an increase in constitutively active IK,Ach
[41,116,122,123] MiR-328 up-regulation with consequent repres-
sion of Cav1.2-translation and Ca2þ -dependent calpain acti-
vation, causing proteolytic breakdown of L-type Ca2þ channels
[41,116]. The rate-dependent up-regulation of IK1 results from a
Ca2þ/calcineurin/NFAT-mediated down-regulation of the inhibi-
tory miR-26, removing translational–inhibition of Kir2.1 [41,116].
Increased IK1 stabilizes AF by abbreviating and hyperpolarizing
atrial cardiomyocyte Aps [41]. Small-conductance Ca2þ-activated
Kþ (SK) currents (ISK) also play a role in AF [41,116]. Computational
modelling shows that increased total inward-rectifier Kþ current
in chronic atrial fibrillation (cAF) is the major contributor to the
stabilisation of re-entrant circuits by shortening APD and hyper-
polarizing the resting membrane potential [41,116].
Atrial tachycardia remodelling reduces Ca2þ-transient ampli-
tude by a variety of mechanisms, contributing to atrial contractile
dysfunction [41,116,124]. Reduced atrial contractility causes atrial
‘stunning’ that may be involved in thromboembolic complications.
Long-term atrial tachycardia remodelling causes conduction
slowing in several animal models, at least partly due to INa down-
regulaton [122]. Heterogeneously distributed gap-junction
uncoupling due to connexin remodelling likely contributes to
atrial conduction slowing [41,116]. Heterogeneity in connexin-40distribution correlates with AF stability in goats with repetitive
burst-pacing-induced AF [125]. Connexin-40 expression decreases
in the PVs of dogs with AF-related remodelling, possibly due to
tachycardia-induced connexin-degradation by calpains [41,116].
Long-term atrial tachycardia/AF may itself cause atrial fibrosis
that contributes to long-term persistence [126]. Rapid atrial firing
promotes fibroblast differentiation to collagen-secreting myofi-
broblasts through autocrine and paracrine mechanisms [32]. Atrial
tachycardia-induced NFAT-mediated decreases in fibroblast miR-
26 may also contribute to structural remodelling. Atrial fibroblasts
have non-selective cation channels of the transient receptor
potential (TRP) family that carry Ca2þ into the cell; the increased
cell-Ca2þ then triggers increased collagen production. Since miR-
26 represses TRPC3 gene expression, miR-26 reductions increase
TRPC3 expression, promoting fibroblast Ca2þ entry that causes
proliferation/myofibroblast differentiation [127]. TRPM7 may
similarly contribute to fibrotic changes in AF [128].
APD shortening in cAF patients also results from increased
inward-rectifier Kþ currents [129], both IK1 and a constitutive
form of IK,Ach [41,116]. Agonist-activated IK,ACh is decreased in right
atrium of AF patients because of a reduction in underlying Kir3.1
and Kir3.4 subunits [129], whereas agonist-independent current is
increased [41,116].
Atrial cardiomyocytes from patients with long-standing per-
sistent AF show spontaneous diastolic SR Ca2þ-release events
(SCaEs) and delayed after depolarizations (DADs) [130]. CaMKII-
dependent RyR2 hyperphosphorylation underlies the SR Ca2þ leak
and SCaEs [32,106,130]. Protein kinase A-dependent RyR2 hyper-
phosphorylation also occurs [130], likely promoting the dissocia-
tion of the inhibitory FKBP12.6 subunit from the RyR2 channel.
Larger inward NCX current may also contribute to the stronger
propensity for DADs [130].
Although initial work pointed to unchanged INa or mRNA
expression of the Nav1.5 a-subunit in AF patients, recent studies
reported reduced peak INa [41,116]. There is also evidence for
increased INa,late, although its functional consequences are less
clear. Altered mRNA and protein levels of connexin-40/-43 may
also contribute to re-entry-promoting conduction abnormalities in
cAF patients. Reduced connexin-40 expression together with
lateralization to the transverse cell membrane may cause hetero-
geneous conduction [41,116].
Overall, ion-channel changes contribute to AF stabilisation and
early recurrence after cardioversion. Ca2þ-handling abnormalities
are involved in atrial ectopy, and atrial fibrosis is important in the
progression of long-term persistent AF to resistant forms. Atrial
fibrillation-induced atrial myopathy has changes that depend on
AF duration. Very short-term AF produces no ultrastructural
alterations, while AF lasting several weeks causes EHRAS I
alterations [13]. Long-term persistent AF produces EHRA III chan-
ges [126].
4.8. Drug-related atrial fibrillation
A large number of drug classes have been associated with the
induction of AF either in patients without heart disease or in
individuals with pre-existing cardiac disorders (Table 4) [131], but
drug-induced AF (DIAF) has received less attention than that it
might deserve. The overall incidence of DIAF is still unknown for
several reasons: (a) the evidence associating specific drugs with AF
has largely been based on anecdotal reports, with very few con-
trolled prospective clinical trials, (b) DIAF is often paroxysmal and
documentation may be difficult/poor, (c) while DIAF is easily
recognised if it occurs just after i.v. drug administrations (e.g.
adenosine or dobutamine), AF episodes can be missed if they
appear after multiple exposures (e.g. chemotherapy), (d) patients
often receive multiple drugs, making the specific culprit agent
Table 4
Drugs reported to induce atrial fibrillation.
Drug group Drugs Mechanism
Bisphosphonates Alendronate, zoledronic acid
Cardiovascular
Inotropics Dopamine, dobutamine, dopexamine, arbutamine,
enoximone, milrinone, levosimendan
Adrenergic stimulation
Vasodilators Isosorbide, losartan, flosequinan Hypotension with probable adrenergic reflex
Cholinergics Acetylcholine Vagal stimulation
Diuretics Thiazides Hypokaliemia
Respiratory System
Sympathicomimetics Pseudoephedrine, albuterol, oriciprenaline, salbutamol,
salmetrol
Adrenergic stimulation
Xanthines Aminophylline, teophylline Adrenergic stimulation
Central Nervous System
Anticholinergics Atropine Adrenergic stimulation
Anticonvulsants Lacosamide, paliperidone
Antidepressants Fluoexetine, tranylcypromine, trazodone Direct cardiodepressant effect, sympathetic tone
Antimigraine Ondasetron, sumatriptan coronary spasm
Antipsychotics Clozapine, loxapine, olanzapine Direct cardiodepressant effect, sympathetic tone
Cholinergics Physostigmine, donepezil Vagal stimulation
Dopamine agonists Apomorphine Vagal activity
Chemotherapeutics Cardiac injury, coronary vasospasm, hypertension, reactive oxygen
species, changes in mitochondrial calcium transport, electrolyte
disturbances, inflammation
Alylating agents Cisplatin, cyclophosphamide, ifosfamide, melphalan
Anthracyclines Doxorubicin, mitoxantrone
Anti-metabolites Capecitabine, 5-fluorouracil, gemcitabine
Antimicrotubule agents Docetaxel, paclitaxel
Tyrosine kinase inhibitors cetuximab, soratenib, sunitinib
Topoisomerase inhibitors amsacrine, etoposide
Monoclonal antibodies Cytokines and
immunomodulators
alemtuzumab, bevacizumab, rituximab, trastuzumab
azathioprine, interferon-gamma, interleukin-2,
lenalidomide
Genitourinary System
Drugs for erectile sildenafil, tadalafil, vardenafil Hypotension with adrenergic reflex dysfunction
Tocolytic drugs b2-adrenoceptor agonists (hexoprenalin, terbutaline),
magnesium sulphate
Hormones
Anabolic-androgenic Structural changes, changes in autonomic activity steroids
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often diagnosed by non-cardiologists, often with an imprecise
description of the arrhythmic event and clinical history [132].
Multiple mechanisms have been suggested to explain the patho-
genesis of DIAF: (a) direct atrial electrophysiological effects like
abbreviated refractoriness, slowed conduction, or triggered activ-
ity due to Ca2þ loading, (b) changes in autonomic tone,
(c) myocardial ischaemia, (d) direct myocardial damage and other
mechanisms such as release of pro-inflammatory cytokines, oxi-
dative stress, hypotension, and electrolyte disturbances [131,132].
In the majority of cases, DIAF is a benign self-limited disorder.
However, DIAF may be clinically serious in polymedicated patients
with underlying comorbidities [132]. Discontinuation of the cau-
sative drug(s) usually leads to cardioversion in few minutes or
hours. When AF persists, treatment is similar to that of non-DIAF
patients [133,134]. Because of the wide range of mechanisms by
which drugs cause AF, the histological changes associated with
DIAF may vary substantially from EHRAS class I–IV (see Table 2 for
reference). Future studies are warranted to assess specific effects
of various drugs on atrial tissue.4.9. Myocarditis
Myocarditis refers to an inflammatory disease of the heart,
which occurs as a result of exposure to external triggers (e.g.
infectious agents, toxins, or drugs) or internal ones like auto-
immune disorders [135,136].The incidence is difficult to ascertain since it depends on the
diagnostic criteria. A likely estimate is 8 to 10 per 100 000 popu-
lation, representing the third leading cause of sudden death after
hypertrophic cardiomyopathy and coronary artery disease [137]. In
autopsy series, the prevalence of myocarditis varies from 2% to 42%
in young adults with sudden death [138,139]. Biopsy demonstrates
an inflammatory infiltrate in 9–16% of patients with unexplained
non-ischaemic dilated cardiomyopathy [140,141].
Myocarditis is defined by the ‘Dallas criteria’ as the presence of
a myocardial inflammatory infiltrate with necrosis and/or degen-
eration of adjacent cardiomyocytes of non-ischaemic nature [142].
According to the type of inflammatory cell, myocarditis may be
subdivided into lymphocytic, eosinophilic, polymorphic, giant-cell
myocarditis, and cardiac sarcoidosis [136].
Atrial fibrillation is frequently part of the clinical presentation
of myocarditis. In 245 patients with clinically suspected myo-
carditis, AF occurred in about 30% [143]. Myocarditis with lone
atrial involvement is rarly diagnosed [144–146]. This may reflect
the fact that atrial myocardium is not methodically sampled either
at autopsy or in routine endomyocardial biopsy. In most such
cases, AF dominated the clinical picture, suggesting a role for
architectural remodelling that interferes with atrial conduction
[9,147]. Giant-cell myocarditis is a distinct – and probably auto-
immune – myocarditis characterised by diffuse infiltration by
lymphocytes and numerous multinucleated giant-cells, frequent
eosinophils, cardiomyocyte necrosis and, ultimately, fibrosis. The
natural course is often fulminant and mortality is high if
untreated. An isolated atrial variant of giant-cell myocarditis was
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described in the English language literature. The atrial variant
appears to have a more favourable course compared with the
classical form [149]. The atrial giant-cell myocarditis may repre-
sent a distinct entity, potentially attributable to atrium-specific
auto-antigens [150]. EHRAS Class IVi is observed in patients with
atrial myocarditis. As myocarditis persists and enters a chronic
phase, characteristics may change to EHRAS Class III (see Table 2).4.10. Atrial cardiomyopathy associated with genetic repolarization
disturbances
Atrial standstill, a severe form of atrial cardiomyopathy, is
associated with combined heterozygous mutations of SCN5A and
Connexin-40 genes [151]. Gain-of-function mutations in Kþ-
channel subunits (e.g. KCNQ1, KCNH2, KCND3, and KCNE5) or loss-
of-function mutations in KCN5A have been identified in AF
patients [152]. Thus, either gain or loss of Kþ-channel function can
cause AF, indicating that repolarization requires optimal tuning
and deficits in either direction can be arrhythmogenic. Recently,
early repolarization or J-wave syndrome has been associated with
AF although, in middle-aged subjects, early repolarization in
inferior leads did not predict AF [153]. A gain-of-function mutation
in KCNJ8, encoding the cardiac Kir 6.1 (KATP) channel, is associated
with both increased AF susceptibility and early repolarization
[154]. There is an established association between atrial arrhyth-
mias and primary ventricular arrhythmia syndromes, which was
first reported among conditions that manifest with obvious
structural abnormalities [155]. Atrial fibrillation is relatively com-
mon in hypertrophic cardiomyopathy (prevalence20%) [156]. In
arrhythmogenic right ventricular cardiomyopathy, an even higher
proportion (up to 40%) of patients may manifest AF [157]. The
association with AF also extends to primary arrhythmia syndromes
without obvious structural heart disease. Supraventricular tachy-
cardias, primarily AF/AFl, have been reported in Brugada syn-
drome [158,159]. Among long QT syndrome (LQTS) patients, pro-
longation of action potentials leading to atrial fibrillation has been
suggested to be an atrial form of ‘torsades de pointes’ [152]. A
subtle form of ‘cardiomyopathy’ that includes increased left atrial
volumes occurs in 12% of LQTS patients [160]. The reports
available mostly implicate genetic variants in Naþ-channel genes
[161]. Patients with early-onset lone AF have a high prevalence of
LQTS-associated SCN5A variants [162]. A mouse model of LQT3 is
prone to atrial arrhythmias due to EADs [163]. There are sporadic
reports of atrial arrhythmias in patients with CPVT [164]. Taken
together, the associations between AF and sudden death syn-
dromes likely reflect common mechanisms between atrial and
ventricular arrhythmogenesis.4.11. Ageing
In elderly dogs, premature impulses show markedly slowed
conduction, associated with a doubling of fibrous-tissue content
APD prolongation and spatial heterogeneity in repolarization
[165,166]. Clinical mapping studies have also demonstrated similar
findings of conduction abnormalities, prolonged refractoriness,
reduced myocardial voltage, and a greater number of double
potentials and fractionated electrograms [167,168]. Perhaps as a
result of these atrial changes, alteration of wavefront propagation
velocities has been described with an inverse correlation to age
[169]. Histologically, fibrotic changes are the most obvious
alteration (EHRAS Class II; see Table 2).4.12. Hypertension
Hypertension accounts for at least one in five incident AF cases
[170]. In hypertensive subjects, both left atrial enlargement and P-
wave changes are predictive of AF occurrence [171,172].
In small animal models, mimicking hypertension by partial
aortic clamping induces LA hypertrophy, fibrosis, connexin-43
down-regulation and slow/inhomogeneous conduction [173].
Prenatal corticosteroid exposure-induced hypertension in sheep
causes atrial conduction abnormalities, wavelength shortening,
and increased AF [174]. Lau et al. utilised a one-kidney one-clip
model to investigate the impact of short- and long-term hyper-
tension on the evolution of an atrial cardiomyopathy [175,176].
Utilisation of this model intrinsically is more reflective of a dis-
ordered renin–angiotensin axis. Short-term hypertension pro-
gressively enlarged the LA, reduced LA emptying fraction, pro-
longed atrial refractoriness, slowed conduction, and caused LA
interstitial fibrosis and inflammatory cell infiltration [175,176]. In
patients with established hypertension and LV hypertrophy, there
is global and regional conduction slowing associated with frac-
tionated electrograms and double potentials along the crista ter-
minalis, along with an increase in low-voltage areas [177].
Importantly, population studies show increased AF risk even
with ‘pre-hypertension’ (systolic blood pressure 130–139 mmHg)
[178]. The ab-normal atrial substrate is reversible, with studies
demonstrating improved electrical and structural parameters and
reduced AF burden following treatment with renin–angiotensin–
aldosterone system blockers [179–181]. In patients with resistant
hypertension and improved blood pressure following renal
denervation, there was a global improvement in atrial conduction
and reduced complex fractionated activity. Histologically, pressure
overload induces hypertrophy of atrial myocytes (EHRAS Class I).
Collagen deposition may also occur (EHRAS II–III) with more
severe hypertension causing LV hypertrophy and diastolic dys-
function (see Table 2).
4.13. Obesity
Several population-based studies have demonstrated a robust
relationship between obesity and AF [182–184]. A recent meta-
analysis estimates a 3.5–5.3% excess risk of AF for every one unit of
body mass index increase [185].
Left atrium dilation and dysfunction are known consequences
of the cardiomyopathy due to obesity [186]. In a sheep model of
obesity, progressive weight gain over 8 months was associated
with increased atrial volume, pressure, and pericardial fat volume
along with atrial interstitial fibrosis, inflammation, and myocardial
lipidosis [187]. This was associated with decreased conduction
velocity, increased heterogeneity of conduction and a greater
inducibility of atrial fibrillation. With more sustained obesity,
animals not only demonstrate progressive atrial changes but also
in areas adjacent to pericardial fat there is infiltration of the atrial
myocardium by fat cells [188].
Obese patients have higher left atrial volume and pressure with
lower left atrial strain associated with shorter refractoriness in the
LA and the PVs [189]. A detailed evaluation of atrial changes
associated with human obesity showed an increase in the left
atrial epicardial fat, a global reduction in atrial conduction velocity,
increased fractionation, and preserved overall voltage but greater
low-voltage areas [190]. The low-voltage areas were observed in
regions adjacent to epicardial fat depots.
Pericardial fat volume has been shown to be associated with AF
incidence, severity, and adversely effects ablation outcome
[191,192]. Epicardial adiposity is associated with altered 3D atrial
architecture, adipocyte infiltration into the myocardium, and atrial
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promotes AF [193–195].
In the ovine model of chronic obesity, weight reduction is
associated with reduction in total body fat, atrial dilatation, and
interstitial fibrosis together with improved hemodynamics, atrial
connexin-43 expression and conduction properties that result in
reduced vulnerability to AF [196]. In humans, aggressive man-
agement of weight and associated risk factors is associated with
favourable changes in pericardial fat volume, atrial size, myo-
cardial mass as well as electrophysiological and electroanatomical
changes along with reduced AF inducibility and burden [197].
Furthermore, weight loss in morbidly obese subjects is associated
with reduced epicardial fat [198]. Weight reduction in obese
individuals can result in regression of LV hypertrophy, reduction in
left atrial size and reduction in AF burden/severity [199–201].
Histologically, fatty infiltrates (EHRAS Class IVf) as well as collagen
depositions are present (EHRAS III; see Table 2).
4.14. Diabetes mellitus
Diabetes is an independent risk factor for development and
progression of AF [202]. In a rat model of diabetes mellitus, atrial
tissue fibrosis deposit is associated with decreased conduction
velocity and greater AF inducibility [203]. Patients with abnormal
glucose metabolism have larger left atrial size, lower left atrial
voltage, and longer left atrial activation time compared with
controls [204]. Insulin resistance is associated with increased left
atrial size and structural heterogeneity [205,206].
Mitochondrial function is impaired, leading to oxidative stress,
in diabetic atria [207]. Oxidative stress and activation of the
advanced glycation end-product (AGE)-AGE-receptor (RAGE) sys-
tem mediates atrial interstitial fibrosis up-regulation of circulating
tissue growth factors and pro-inflammatory responses [207,208].
In addition, prolonged hyperglycaemic stress leads to accumula-
tion of AGE-RAGE and nitric oxide inactivation, leading to endo-
thelial dysfunction and myocardial inflammation [209].
Hyperglycaemia and AGE-RAGE ligand interactions lead to
decreased phosphorylation of connexin-43, potentially impairing
intercellular coupling [210]. Advanced glycation is also related to
alterations in myocardial calcium handling and hence contractility
[211]. These findings could explain the electrophysiological
alterations that serve as a central mechanism of the vulnerability
to AF in diabetes [212].
Aggressive treatment of diabetes and adequate glycemic con-
trol may prevent or delay the occurrence of AF, despite little direct
evidence of the effects of anti-diabetic drugs on AF. Peroxisome
proliferator-activated gamma receptor agonists may offer protec-
tion against AF beyond glycemic control, due to their anti-
inflammatory, antioxidant, and anti-fibrotic effects [213]. However,
caution should be taken in extrapolating these experimental
findings to patients with diabetic cardiomyopathy. Histologically,
changes in the atrial myocytes are the initial findings without
significant fibrosis (EHRAS I). Later on the disease tissue appear-
ance may change to EHRAS Class III and EHRAS Class IV (see
Table 2).
4.15. Atrial cardiomyopathy due to valvular heart disease
Mitral valve disease (MVD) and aortic stenosis (AS) have been
associated with atrial structural remodelling and a propensity for
AF. Although secondary atrial cardiomyopathy is most often
associated with age, hypertension, and heart failure in developed
countries, RHD is responsible for over 40% of AF in the developing
world [214].4.15.1. Mitral stenosis
In atria from 24 patients with isolated MS and normal sinus
rhythm undergoing mitral valvuloplasty, John et al [215]. reported
unchanged or an increased effective refractory period (ERP),
widespread and site-specific conduction delay, myocyte loss and
patchy electrical scar, suggesting that structural changes and their
electrophysiological consequences precede the development of AF.
Factors associated with these structural changes include direct
myocardial effects (pathognomonic inflammatory Ashoff bodies),
ultrastructural changes, atrial fibrosis, immunoactive cytokines,
and matrix metalloproteinase remodelling (decreased MMP-1 and
MMP-3) [215–217]. Reverse atrial remodelling (an immediate
reduction in LA pressure and volume and an improvement in
biatrial voltage; and further increases in RA voltage 6 months
later) was demonstrated in 21 patients with isolated MS under-
going commissurotomy [218]. In contrast, atrial remodelling did
not reverse in patients with lone AF undergoing successful AF
ablation; indeed, substrate abnormalities progressed (decreased
voltage and increased regional refractoriness) over the subsequent
6–14 months [219].
Atrial enlargement and fibrosis are important determinants for
the development and maintenance of AF. Increases in collagen I
and collagen III (the latter which increase in cultured fibroblasts
exposed to mechanical stretch) [220] were seen in patients with
AF and MVD, but only type I was seen in patients with lone AF
[221]. Cellular decoupling and myocyte isolation, tissue anisotropy,
and conduction inhomogeneities were considered the substrate
for local re-entry and arrhythmia.
4.15.2. Mitral regurgitation
Verheule et al [222]. found changes in atrial tissue structure
and ultrastructure 1 month after creating severe mitral regur-
gitation (MR) by partial mitral valve avulsion. Effective refractory
periods were increased homogeneously and sustained AF (.1 h)
was inducible in 10 of 19 MR dogs; in this model, there were no
differences in either atrial conduction pattern or velocities. Inter-
stitial fibrosis, chronic inflammation, and cellular glycogen accu-
mulation were noted in the dilated left atria, but myocyte hyper-
trophy, myolysis, and necrosis were absent. In contrast, myocyte
hypertrophy, dedifferentiation, and degeneration and fibrosis are
described in pigs with surgically created chronic MR [223] and
patients with MR [12,224].
High-density oligonucleotide microarrays, enrichment analysis,
and a differential proteomics approach were used to characterize
the molecular regulatory mechanisms and biological processes
involved in the atrial myopathy that is seen in pigs with moderate
to severe chronic (6 and 12 months) MR [225]. Renin-angiotensin-
system and peroxisome proliferator-activated receptor signalling
pathways and genes involved in the regulation of apoptosis,
autophagy, oxidative stress, cell growth, and carbohydrate meta-
bolism were differentially regulated [225]. MLC2V (a marker of
cardiac hypertrophy and important in the regulation of myocyte
contractility) had the highest fold change in the MR pigs. Increased
activity of a membrane-bound containing NADPH oxidase in atrial
myocytes, which correlated with the degree of cellular hyper-
trophy and myolysis, was demonstrated in patients with isolated
severe MR. The authors suggest that atrial stretch-induced NADPH
oxidase activation and intracellular oxidative stress contributes to
apoptosis, atrial contractile dysfunction, and atrial dilatation [226].
Correction of MR reverses many features of atrial remodelling
and corrects functional abnormalities. Early LA reverse remodel-
ling (45% reduction of mean LA maximal volume) and increased
active atrial emptying was found in the early (30 day) post-
operative period in 43 patients undergoing mitral valve surgery
(successful repair or replacement) for chronic organic MR [227]
and a similar improvement at 6 months was reported by Dardas et
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finding in MVD, although the histological appearance of the tissue
may vary substantially over time and interindividually and,
therefore, all EHRAS classes may be found in the tissue (see Fig. 1;
Table 2).
4.15.3. Aortic stenosis
Although AS is associated with chronic AF [229], animal models
of AS and atrial remodelling are lacking. Kim et al [173]. studied
atrial electrical re-modelling in excised perfused hearts in a rat
model of increased afterload simulating AS (ascending aortic
banding), which produced LVH without systemic hypertension,
heart failure, or neurohormonal activation. Banded hearts showed
marked LA hypertrophy and fibrosis at 14 and 20 weeks post-
operatively. The incidence and duration of pacing-induced AF was
increased at 20 weeks and was associated with decreased mean
vectorial conduction velocity and inhomogeneity of conduction,
decreased expression of connexin-43, but without changes in ERP.
Importantly, atrial remodelling was not present at 8 weeks, when
the greatest degree of LVH was present [173].
Left atrium volumes are higher in patients with AS compared
with controls and decrease significantly after valvuloplasty [230].
Plasma natriuretic peptide (ANP) levels are higher in symptomatic
than asymptomatic patients with AS [231] and N-ANP levels pre-
dict atrial remodelling and late (2 month) post-operative AF after
surgery for AS [232].
Taken together, these data support the notion that substrate-
based AF is a consequence of the abnormal haemodynamics and
atrial remodelling that accompany valvular heart disease. In this
instance, atrial remodelling is the consequence of multiple biolo-
gical processes that create structural and ultrastructural abnorm-
alities and a change in conduction (as opposed to refractoriness)
that favours the development and maintenance of AF. Histologi-
cally, EHRAS Class III is the most prominent finding, although the
histological appearance of the tissue may vary substantially over
time and interindividually (see Figs. 1–3; Table 2). Atrial pathology
often also affects specialised conduction system tissues like the
sinus and AV nodes. However, these changes are beyond the scope
of the present consensus report, which focuses on atrial cardio-
myocytes and tissue.5. Impact of atrial cardiomyopathies on occurrence of atrial
fibrillation and atrial arrhythmia
Controversy about the mechanism of AF has been alive for over
100 years, yet given the continued increase in worldwide burden
of AF [233], ongoing investigation will drive improved treatment
and prevention. Currently, there are two opposing sides in the
debate about re-entrant mechanisms in AF. On one side are those
who promote variants of the original idea of Gordon Moe that
fibrillation, whether atrial or ventricular, results from the con-
tinued random propagation of multiple independent electric
waves that move independently throughout the atria [234,235].
On the other side are those who adhere to the theory that fibril-
lation is a consequence of the continued activity of a few vortices
(rotors) that spin at high frequencies, generating ‘fibrillatory con-
duction’ [236,237]. In either case, arrhythmia maintenance is
favoured by abbreviated APD/refractory period [13,238,239].
Another pre-requisite of the multiple wavelet hypothesis is that
there should be slow conduction, which is not the case for rotors.
According to rotor theory, slowing of conduction is established
dynamically by the curvature of the rotating wave front, which is
steepest near the rotation centre, at which refractory period is
briefest and conduction velocity is slowest [240]. Which of theabove two mechanisms prevails in human AF has not been fully
established, yet [241].
Regardless of the mechanism that maintains it, AF leads to
high-frequency atrial excitation, which if sustained, results in ion-
channel remodelling that further abbreviates the APD and refrac-
tory period to boost its stabilisation. Such AF-induced electrical
remodelling is reversible in the short term (minutes, hours, or
days), but less so when lasting months or years. For a detailed
discussion of AF-induced remodelling, see chapter 3. How these
changes contribute to AF perpetuation in the long term has not
been fully determined.
In a recent study using a sheep model of persistent AF induced
by intermittent atrial tachypacing there was a progressive spon-
taneous increase in the dominant frequency (DF) of AF activation
after the first detected AF episode [240,242]. The results suggested
that, unlike the tachypacing induced electrical remodelling that
can occur over minutes or hours, there existed a protracted, slowly
progressing electrical and structural remodelling secondary to AF
that sustains for days or weeks [240,242]. In addition, a consistent
left-vs.-right atrial DF difference correlated with the presence of
rotors, DF gradients, and outward propagation from the posterior
LA during sustained AF in the explanted, Langendorff-perfused
sheep hearts [242], and an underlying basis is seen in humans
[243]. The DF of non-sustained AF increases progressively at a rate
(dDF/dt) that accurately predicts the transition from episodic, non-
sustained AF to persistent, long-lasting AF [126]. Although fibrosis
developed progressively [126], it is unknown what role if any
fibrosis played in rotor acceleration or stabilisation. Other studies
using different animal models have also demonstrated that long-
term atrial tachypacing results in atrial fibrosis [244], with con-
comitant release of cytokines that are known to modify atrial
electrical function [245]. In the sheep model, atrial structural
changes leading to PLA enlargement likely made rotors less likely
to collide with anatomic boundaries, thus contributing to their
stabilisation and AF persistence [242,246].
Distinct stresses of the atrial myocardium could contribute to
the transformation of atrial cardiomyopathy into an arrhythmo-
genic substrate for AF. For instance, mechanical stress is a major
regulator of cardiac electrical properties. The two atria are parti-
cularly sensitive to changes in mechanical coupling due to their
‘reservoir’ position and their function of ‘pressure sensor’ with a
specific endocrine role, i.e. the secretion of natriuretic peptides.
Many mechanosensors are expressed in the atrial myocardium and
contribute to the interplay between membrane electrical proper-
ties, mechanical stresses, and myocardial wall deformation [247].
Recently, it has been reported that shear stress of atrial cardio-
myocytes regulates the surface expression of voltage-gated
potassium channels via the stimulation of the integrins that link
myocytes to the extracellular matrix [248,249]. During atrial
haemodynamic overload, the mechano-sensor signalling path-
ways, are constitutively activated, such that myocytes are no
longer able to respond to shear stress. This process results in the
acceleration of atrial repolarization and could contribute to AF
vulnerability [249].
Oxidative stress is also thought to be important in AF-induced
atrial remodelling leading to cardiomyopathy and AF perpetuation
[250]. How-ever, the manner in which reactive oxygen species
(ROS) mediate atrial ionic remodelling is inadequately understood.
NOX2/4 activity increases in fibrillating atria and is a potential
source of ROS in AF. Mitochondrial ROS is potentially another
important source of oxidative stress; mitochondrial dysfunction
has been demonstrated in AF. It remains to be determined whe-
ther atrial oxidative stress directly affects atrial APD and refrac-
toriness and thus contributes to rotor acceleration and stability in
AF. Several sarcolemmal ionic currents are directly or indirectly
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human AF has not been demonstrated.
Sustained AF activates the release of pro-inflammatory cyto-
kines and hormones related to cardiovascular disease and tissue
injury, including angiotensin-II (Ang-II), tumour necrosis factor
(TNF)-a, interleukin (IL)-6, and IL-8 [252]. Pro-inflammatory sti-
muli such as NOX-derived ROS, growth factors, and other hor-
mones has been demonstrated to have a role in Ang-II function
[253]. However, the precise molecular modifications of the puta-
tive signalling targets of ROS after Ang-II stimulation are yet to be
identified. Knowing which NOXs are activated by Ang-II in the
normal atria may help generate better interventions aimed at
preventing AF associated with Ang-II activation. Ang-II is a well-
known trigger of fibroblast activation and differentiation into
myofibroblasts, which are key factors in the generation of fibrosis.
Pro-inflammatory cytokines also promote ion-channel dysfunc-
tion, which together with myocyte apoptosis and extracellular
matrix remodelling predisposes patients to AF.
Recently, atrial adipose tissue has emerged as a potential player
in the pathophysiology of AF [3,254]. In addition to its paracrine
effects [192], adi-pose tissue can infiltrate the subepicardium of
the atrial myocardium and become fibrotic [255] contributing to
the functional dissociation of electrical activity between epicardial
layer and the endocardial bundle network, favouring wavebreak,
and rotor formation. Lone AF or rapid atrial pacing promotes
adipogenesis through the regulation of genes specific to metabolic
adaptation. Therefore, it is possible that the accumulation and
infiltration of adipose tissue reflects metabolic stress secondary to
excessive work of the atrial myocardium [191]. Furthermore, adi-
pose tissue can induce fibrosis and alter gene-expression patterns
[195,256].6. Atrial cardiomyopathies, systemic biomarkers, and atrial
thrombogenesis
6.1. Atrial cardiomyopathies and systemic biomarkers
6.1.1. Atrial inflammation and inflammatory biomarkers
Infiltration of neutrophils, macrophages, and lymphocytes
accompanies surgical injury or pericarditis, promoting the devel-
opment of atrial fibrosis, resulting in heterogeneous and slowed
conduction, a risk factor for re-entrant arrhythmia [257–261]. This
provides a mechanistic link between inflammatory activation and
atrial arrhythmogenesis. Anti-inflammatory interventions such as
prednisone are effective in preventing neutrophil infiltration in
sterile pericarditis and in suppressing pacing-inducible atrial
flutter [262], and steroid pre-treatment has been found to reduce
the incidence of postoperative AF in an appropriately powered
randomized, clinical trial [263]. An ongoing trial studies the effect
of colchicine (NCT 001128427).
In a mouse model of persistent hypertension, Ang-II infusion
promotes increased atrial abundance of myeloperoxidase (MPO, a
neutrophil and macrophage oxidant-generating enzyme) and
promotes atrial fibrosis [261]. In MPO knockout mice, the profi-
brotic response to A-II infusion was eliminated. Angiotensin II and
endothelin-1 are linked to inflammatory and proarrhythmogenic
atrial remodelling [2,264–266]. This evidence suggests that
inflammatory cell infiltration has an important role in promoting
the creation of a substrate for AF, as a result of conduction het-
erogeneity and slowing, both in the setting of cardiac surgery and
beyond.
6.1.2. Systemic inflammatory activation in atrial fibrillation
In addition to haemodynamic stress-induced cellular inflam-
mation of the atria, a cross-sectional study demonstrated that AFwas associated with higher plasma levels of C-reactive protein
(CRP), a sensitive but non-specific biomarker of systemic inflam-
mation produced by the liver [267]. A follow-up secondary ana-
lysis of the participants Cardiovascular Health Study participants
further revealed that elevated CRP predicted incident AF [268].
Subsequent studies have demonstrated relationships between
several different serologic markers of inflammation and AF,
including IL-6 [269], TNF-a [270], aldosterone [271] and simple
white blood cell counts [272]. Analyses of multiple inflammatory
biomarkers within the same study have suggested that IL-6 and
osteoprotegerin [273] may be especially important. The relation-
ship between IL-6 and AF may be mediated by left atrial enlar-
gement [269].
While evidence that inflammatory markers presage the devel-
opment of AF has been replicated [268,274], there are also mul-
tiple studies to dem-onstrate that atrial arrhythmias likely con-
tribute to inflammation: specifically, cardioversion of AF [275] as
well as ablation of either AF [276] or atrial flutter [277] has
resulted in a decrease in inflammation. Indeed, Marcus et al.
demonstrated that the rhythm at the time of the blood draw (AF
vs. sinus) was an important determinant in detecting an elevated
CRP or IL-6 level [278]. Taken together, these data suggest that the
relationship between inflammation and AF may be bidirectional
and progressive.
6.1.3. Intra-atrial sampling studies
As the enhanced risk of stroke in the setting of AF has been
attributed to status of blood flow and in particular thromboemboli
originating in the left atrial appendage, there has been an interest
in determining whether peripheral blood can adequately reflect
the hypercoagulability that may be present locally within the atria
(see Fig. 10) [279]. The first intra-atrial sampling study failed to
identify evidence of statistically significant differences between
several markers of hypercoagulability in right and left atrial vs.
femoral vein and arterial samples among persistent AF patients
with MS [280]; of note, the same markers revealed statistically
significant differences when compared with normal controls
without AF [279]. In contrast, a subsequent study demonstrated
that platelet activation acutely increased in coronary sinus blood
in AF, while systemic platelet activation (obtained from the
femoral vein) revealed no such change [281].
A similar approach to multi-site sampling has also been applied
to better understand the relationship between inflammation and
AF. Liuba et al. found higher levels of IL-8 in the femoral vein, right
atrium, and coronary sinus than the left and right upper PVs
among eight permanent AF patients (without any such differences
10 paroxysmal AF patients or 10 controls) [280].
6.1.4. Practical implications and use of systemic biomarkers
Systemic biomarkers have been used to predict development of
AF and/or its complications (Table 5). Various studies have
examined the role of inflammatory indices, natriuretic peptides,
injury markers, etc. in predicting incident AF, especially in the
post-surgery setting. Many of these bio-markers are non-specific,
and high levels may reflect infection or sepsis, an acute phase
reaction, etc [282–284].
Adding BNP and CRP to a prediction score derived from
CHARGE-AF (which included data from the Atherosclereosis Risk
in Communities Study (ARIC), Cardiovascular Health Study (CHS),
the Framingham Heart Study, the Age, Gene/Environment Sus-
ceptibility Reykjavik Study (AGES), and the Rotterdam Study) and
utilising age, race, height, weight, systolic and diastolic blood
pressure, current smoking, use of antihypertensive medication,
diabetes, history of myocardial infarction and history of heart
failure [285] improved the statistical model [286]. Once again, the
addition of CRP did not meaningfully improve the model.
Fig. 10. Concept of ‘endocardial remodelling’ in fibrillating atria. In accordance to Virchow's triad hypercoagulability, flow abnormalities, and endothelial changes must co-
exist to induce thrombogenesis at the atrial endocardium. Molecular studies have revealed substantial endocardial changes in left atrial tissue samples. Prothrombogenic
factors (vWF, adhesion molecules like VCAM-1, P-selectin etc; green) are expressed at the surface of endothelial cells causing an increased adhesiveness of platelets and
leucocytes to the atrial endocardium. This initiates atrial thrombogenesis at the atrial endocardium. Several clinical factors like diabetes mellitus, heart failure ageing etc.
(CHA2DS2VASc Parameters) increase molecular alterations (oxidative stress pathways etc.) within myocytes and endothelial cells, and thereby, increase the expression of
prothrombogenic factors. These alterations are not directly related to the presence of absensce of atrial fibrillation in the surface ECG, and therefore, help to explain, why
thrombogenesis is increased even during episodes of sinus rhythm.
Table 5
Coagulations markers in atrial fibrillation.
Study AF group(s) Control group(s) Significant abnormalities found in AF (increase in coagulation markers)a
Gustafsson (1990) [507] 20 (with stroke) 40 (normal without stroke) D-dimers, vWF irrespectively of history of stroke
20 (without stroke) 20 (with stroke)
Kumagai (1990) [508] 73 73 D-dimers
Asakura (1992) [509] 83 (normal) PF1þ2, TATIII complex
Sohara (1994) [510] 13 (paroxysmal) (normal) TATIII complex (no difference in D-dimers),
Lip (1995) [511] 87 158 D-dimers, vWF
Lip (1996) [512] 51 26 (healthy) D-dimers
Kahn (1997) [513] 50 (without prior stroke) 31(without prior stroke) Fibrinogen in AF without stroke vs. controls without stroke (no difference
was seen between groups with prior stroke)25 (with prior stroke) 11 (with prior stroke)
Heppell (1997) [514] 19 with thrombus in LA not applicable D-dimers, vWF, TATIII complex if LA thrombus
90 without thrombus in LA
Shinohara (1998) [515] 45 (non-valvular) not applicable D-dimers, TATIII complex in patients with low vs. high LAA velocity
Feinberg (SPAF III) (1999)
[516]
1531 not applicable No association of PF1þ2 with thromboembolism
Mondillo (2000) [517] 45 35 (healthy) D-dimers, vWF, s-thrombomodulin
Fukuchi (2001) [518] 16 27 (cardiac without AF) vWF in LA appendage tissue
Conway (2002) [296] 1321 vWF in high-risk group for stroke
Kamath (2002) [519] 93 50 (normal) D-dimers
Vene (2003) [520] 113 D-dimers in patients having cardiovascular events vs. no event
Nakamura (2003) [521] LA appendage tissue of 7 non-
valvular
4 non-cardiac death vWF, TF
Conway (2003) [297] 994 not applicable vWF not associated of with risk of stroke,
vWF independently associated with vascular events
Kamath (2003) [522] 31 (acute onset) 31 (healthy) Haematocrit raised in acute AF
93 (permanent) D-dimers in permanent AF (but not in acute AF)
Sakurai (2004) [523] 28 (AFL) 27 D-dimers if impaired LAA function
Inoue (2004) [524] 246 (non-valvular) 111 D-dimers in patients having risk factors, PF1þ2 (NS)
Kumagai (2004) [525] 16 (post mortem) vWF and protein in patients with enlarged atrium
Marin (2004) [526] 24 (acute onset) 24 (CAD patients in sinus rhythm) D-dimers, vWF, s-thrombomodulin (no longer different after
cardioversion)24 (chronic) 24 (healthy)
Nozawa (2004) [527] 509 111 (healthy) D-dimers, PF1þ2 (NS)
Freestone (2005) [528] 59 40 (healthy) vWF
Nozawa (2006) [295] 509 (non-valvular) D-dimers (but not PF1þ2) predictive for thromboembolic events
D-dimers, PF1þ2, platelet factor 4, b-thromboglobulinOhara (2007) [294] 591 (non-valvular) 129
D-dimers, PF1þ2 (correlated with presence of risk factors for stroke)
AF, atrial fibrillation; AFL, atrial flutter; CAD, coronary artery disease; LA, left atrial; LAA, left atrial appendage; NS, non-significant; vWf, von Willebrand factor; PF1þ2,
prothrombin fragment 1þ2; TATIII, thrombin-antithrombin III; TF, tissue factor; s-thrombomodulin, soluble-thrombomodulin.
a Significantly different in AF group, unless otherwise indicated.
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matrix modulators (matrix metalloproteinases, MMPs, and their
tissue inhibitors, TIMPs) and AF risk, only elevated MMP9 levels
were significantly associated with AF risk [287]. Proteases having
desintegrin and metalloprotease activities (ADAM) are related to
atrial dilatation and thereby influence mechanical performance of
the atria [288].
The clinical benefit of considering biomarkers associated with
AF is questionable unless there is clear evidence of a direct benefit
in AF risk prediction and management- this has not been achieved
to date.
6.2. Prothrombotic indices – coagulation, platelets
Over 150 years ago, Virchow proposed a triad of abnormalities
that contributed to thrombus formation (thrombogenesis), that is,
abnormalities of vessel wall, abnormal blood flow and abnormal
blood constituents (Fig. 10). In the setting of AF, abnormalities of
vessel walls are evident by the association of thromboembolism
with structural heart disease (eg. mitral valve stenosis) and com-
plex aortic plaque, as well as endothelial damage/dysfunction,
whether recognised by biomarkers (eg. von Willebrand factor
(vWF), tissue plasminogen activator, tPA), immunohistochemistry
studies of the left atrial wall, electron microscopy, or by functional
studies (eg. flow mediated dilatation) [289]. Abnormal blood flow
in AF can be visualised by spontaneous echocontrast in the LA, as
well as low left atrial appendage Doppler velocities. Abnormal
blood constituents in AF are evident from abnormalities of coa-
gulation, platelets, fibrinolysis, inflammation, extracellular matrix
turnover, etc. that are all directly or indirectly associated with
thrombogenesis, or a predisposition to the latter. While abnorm-
alities of platelets are often evident in AF, they may be more
reflective of associated vascular disease or comorbidities than of
AF per se [290,291]. Indeed, thrombus obtained in AF is largely
fibrin-rich (‘red clot’) compared with arterial thrombus, which is
largely platelet-rich (‘white clot’), providing a mechanistic expla-
nation for the role of anticoagulation therapy, rather than anti-
platelet therapy for AF-related thromboembolism [291,292].
The concept of AF being a prothrombotic or hypercoagulable
state was first proposed in 1995 [293]. Many prothrombotic indi-
ces in AF have been related to subsequent stroke and throm-
boembolism, whether in non-anticoagulated or anticoagulated
subjects (Fig. 10). Initial studies showed that coagulation-related
factors, such as fibrin D-dimer (an index of fibrin turnover and
thrombogenesis) were related to stroke risk strata as well as an
adverse prognosis from thromboembolism, whether or not
patients were anticoagulated [294–297]. In contrast, there was no
prognostic advantage of platelet indices [295,298,299].
6.2.1. Prediction of thrombogenesis
Addition of vWf refines clinical risk stratification in AF, first
shown in the non-anticoagulated or suboptimally anticoagulated
patients from the SPAF study [300]. More recently, vWf has been
related to thromboembolism as well as bleeding risks in antic-
oagulated AF patients [301]. Ancillary studies from large Phase
3 anticoagulation trials have reported prognostic implications for
increased levels of D-dimer, troponin, natriuretic peptides, and
novel biomarkers (e.g. GDF15) [302–304]. Many of these studies
have been performed in selected clinical trial cohorts, and the
prognostic role in risk stratification requires prospective testing in
unselected large ‘real-world’ cohorts with a broad range of stroke
risk and renal function. As in the case of AF prediction, evidence
for the additive value of biomarkers for stroke risk prediction from
large prospective non-anticoagulated ‘real-world’ cohorts is lim-
ited [305]. Endocardial thrombogenic alterations in diseased atria,
which appear to be related to oxidative stress, appear to contributeto clot formation, particularly in the left atrial appendage [306–
310]. Thus, the impact and the relation between EHRAS Classses
and the extend of endocardial thrombogenic alterations have to be
assessed in future studies. Interestingly, duration of AF does not
correlate with the extent of abserved endocardial changes [309].7. Imaging techniques to detect atrial cardiomyopathies
mapping and ablation in atrial cardiomyopathies
It is well established that an enlarged LA is associated with
adverse cardiovascular outcomes [311–316]. In the absence of
MVD, an increase in LA size most commonly reflects increased
wall tension as a result of increased LA pressure [317–320], as well
as impairment in LA function secondary to atrial myopathy
[321,322]. A clear relationship exists between an enlarged LA and
the incidence of atrial fibrillation and stroke [323–332], risk for
overall mortality after myocardial infarction [321,322,333,334],
risk for death and hospitalisation in patients with dilated cardio-
myopathy [335–344], and major cardiac events or death in
patients with diabetes mellitus [345]. left atrium enlargement is a
marker of both the severity and chronicity of diastolic dysfunction
and magnitude of LA pressure elevation [317–320]. A recent con-
sensus report on multi-modality imaging for AF patients sum-
marizes the current status of atrial imaging in more detail [346].
7.1. Echocardiography
Echocardiography is the imaging modality of choice for
screening and serially following patients with diseases involving
the LA morphology and function [347].
For assessment of atrial size, most widely reported is the linear
dimension in the parasternal long-axis view using M-mode or
2 delayed enhancement (DE) [324–339,345,347–349]. However,
due to the complex 3D nature of the atrium and the non-uniform
nature of atrial remodelling, this measurement frequently does not
provide an accurate picture of LA size [350–354]. Thus, when
assessing LA size and remodelling, the measurement of LA volume
is a more powerful prognostic indicator in a variety of cardiac
disease states [329,331,333–339,345,347–360]. Two-dimensional
echocardiographic LA volumes are typically smaller than those
reported from computed tomography or cardiac magnetic reso-
nance imaging (CMR) [361–365]. Left atrium volume from 2D
images is best measured using the disk summation algorithm
because it includes fewer geometric assumptions [366,367]. The
advent of 3-D ECHO has improved the accuracy of ECHO volume
measurements which correlate well with cardiac computed
tomography [368,369] and magnetic resonance imaging [370,371].
Compared with 2D assessment of LA volume, 3DE also has
superior prognostic prediction [372,373].
The recommended upper normal indexed LA volume is 34 mL/
m2 for both genders which fits well with a risk-based approach for
determination of cut-off between a normal and an enlarged LA
[323,357–359].
7.2. Left atrial function by Doppler echocardiography
Left atrium function can be assessed by pulsed-wave Doppler
measurements of late (mitral A) diastolic filling. Multiple studies
have used this parameter as an index of LA function assessment,
but it is affected by age and loading conditions [317,374–382]. The
PV atrial reversal velocity has also been used as a measurement of
LA function [317,377,379–382]. In the presence of reduced LV
compliance and elevated filling pressures, atrial contraction results
in significant flow reversal into the PVs [80,81]. Studies have also
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accurate marker of atrial function [383,384].
7.2.1. New echocardiographic techniques
Two-dimensional speckle-tracking echo has been used as a
more sensitive marker to detect early functional remodelling
before anatomical alterations occur [385–400].
Strain (S) and strain rate (SR) imaging provide data on myo-
cardial deformation by estimating spatial gradients in myocardial
velocities [385,388,392,393,401–405]. This technique has been
used as a surrogate of LA structural remodelling and fibrosis [388–
393]. Interestingly, LA dysfunction with changes in strain and
strain rate has been observed in patients with amyloidosis in the
absence of other echocardiographic features of cardiac involve-
ment [402]. Abnormalities in atrial strain have been observed in
diverse conditions, including AF, valvular pathology, heart failure,
hypertension, diabetes, and cardiomyopathies [388,389,396–400].
Population-based studies have demonstrated the prognostic value
of LA strain analysis for long-term outcome [388,394].
Less research and fewer clinical outcomes data are available on
the quantification of RA size. Right atrial volumes are also under-
estimated with 2D echocardiographic techniques compared with
3DE [343,406,407].
7.3. Cardiac computed tomography
Cardiac CT may be used for accurate assessment of atrial
volumes. Volumetric data from cardiac computed tomography
(CCT) are comparable to data generated by CMR and 3D echo-
cardiographic imaging and is superior to 2D echocardiography
[371]. The LA volume prior to catheter ablation and the presence of
asymmetry of chamber geometry predicts the likelihood of
maintaining sinus rhythm post-procedure [408]. As the LA enlar-
ges, the shape of the LA roof initially becomes flat and then
becomes coved, and this progression may correlate with devel-
opment of non-PV substrate in patients undergoing AF ablation
[409].
CCT may also be used to screen for thrombus prior to AF
ablation. The diagnostic accuracy of CT has been studied by mul-
tiple groups, with a systematic review of 19 studies and 2955
patients reporting a sensitivity and specificity of 96 and 92%,
respectively, translating to a positive predictive value of 41% and a
negative predictive value of 99% [410]. Diagnostic accuracy
increased to 99%, with 100% specificity, when delayed imaging was
performed. An advantage of using CT imaging to exclude thrombus
is that CCT is frequently performed prior to AF ablation for inte-
gration into the electroanatomic mapping systems routinely used
during AF ablation procedures. CCT can also provide accurate
information about PV anatomy and variants and correlates well
with CMR in that regard [411].
7.4. Magnetic resonance imaging of the atrium
Over recent years CMR has been used in clinical and research
settings to provide gold standard volumetric assessments of
chamber structure and function. Drawbacks are that CMR is
expensive and has more limited availability than echocardio-
graphy. Recently, contrast-enhanced CMR with gadolinium has
been used as a technique to detect atrial fibrosis [412]. Although
these methods are still in relatively early stages and have not been
extensively reproduced, the ability to identify early degrees of
atrial structural change would no doubt enhance our ability to
detect varying degrees of remodelling that may not be as clear
from volumetric or functional assessment. In addition to late-
gadolinium-enhanced (LGE) CMR to detect replacement fibrosis,
post-contrast T1 mapping [413,414] has been used to quantifydiffuse interstitial fibrosis. Both techniques have been correlated
with bipolar voltage measured during invasive mapping [412].
However, these techniques require specialised post-imaging pro-
cessing. While they are commonly used for ventricular imaging,
they have not been widely employed for atrial imaging because of
the technical challenges in achieving adequate image resolution in
the thin-walled atrium [415].
Using a systematic scoring system for the extent of delayed
enhancement, a recently-published multicentre study has related
the extent of LGE CMR detected fibrosis to the outcome of AF
ablation [416]. The risk of recurrent AF increased from 15% for
stage I fibrosis (,10% of the atrial wall) to 69% for stage IV fibrosis
(Z30% of the atrial wall). The authors suggested that CMR quan-
tification of fibrosis may play a role in the appropriate selection of
patients most likely to benefit from AF ablation. Late-gadolinium-
enhanced CMR has also been used to predict development of sinus
node dysfunction [417], stroke risk [418], and progression of atrial
fibrillation from paroxysmal to persistent [419]. However, various
studies have highlighted the need to further improve the methods
of accurately identifying replacement fibrosis and to improve
reproducibility of data analysis before LGE CMR can be considered
a routine clinical tool [420,421].
Recently, a number of studies have used CMR DE late gadoli-
nium enhancement (LGE) in order to non-invasively characterize
the extent and distribution of scarring present following AF abla-
tion [422–424]. Several studies observed that patients with more
extensive scar at 3 months (or greater percentage scar around the
PV circumference) had a lower AF recurrence rate [423,425].
Another study showed a correlation between measured contact
force at the time of ablation, and the extent of CMR determined
scar development [426]. Other studies have shown a concordance
between scar around the PVs and low-voltage regions on invasive
electroanatomic mapping (EAM) [427,428]. Isolation of PVs at
repeat procedures could be achieved guided by the imported MR
image to identify the gaps [427,428]. However, other studies found
no association between CMR scar gaps and mapped PV recon-
nection sites. A study in 50 paroxysmal AF patients undergoing
either wide area or ostial ablation found that the proportion of
patients in whom CMR could correctly identify the distribution of
ablation lesions varied from as low as 28% to 54% depending on
the technique used [429]. These authors concluded that LGE
imaging of atrial scar was not yet sufficiently accurate to reliably
identify ablation lesions or to determine their distribution. Whe-
ther CMR will have the resolution to detect such focal regions
where scar is incomplete remains uncertain. Of note, Harrison
et al. used an animal model to correlate lesion size on CMR with
lesion volume at pathology. The correlation depended critically on
the definition of pixel intensity used to define scar with small
changes in definition leading to large changes in estimated scar
volume [415].
7.5. Imaging with electroanatomic mapping
Electroanatomic mapping systems have become the standard
for invasive substrate characterisation of atrial cardiomyopathies.
Using various technologies, these systems allow for rapid char-
acterisation and reproduction of atrial anatomy with 3-D display
rendering. Anatomic variations in PV anatomy, including common
ostium or additional veins, may be identified. Visualisation soft-
ware allows for accurate measurements of atrial distances [430]
and gross volumetric data but assessment of venous diameter may
be suboptimal owning to venous susceptibility to distortion.
Anatomic imaging of the atria may be enhanced with the co-
registration of DICOM images from previously acquired cardiac
MRI or CT or with the use of real-time contrast angiography or
intracardiac echocardiogram.
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enables the assessment of the atrial substrate through the geo-
graphic display of unipolar and bipolar signal amplitude data, as
well as other signal characteristics, on rendered atrial surfaces.
Regions of low-voltage, electrical silence, fractionation, or double
potentials are reputed to correlate with underlying atrial fibrosis,
surgical patches, or scar. In the same way, electrical activation of
the atrium may be imaged allowing for assessment of regional
changes in conduction velocity [431] that may be proarrhythmic
and support the perpetuation of atrial fibrillation. The use of EAM
for activation mapping of atrial arrhythmia will be discussed in the
subsequent section on ablation techniques.
Electroanatomic mapping has been used to image the electro-
anatomic substrate of atrial cardiomyopathy associated with sinus
node disease [432], rheumatic MS [215], atrial septal defect
[218,431], CHF [433], obstructive sleep apnoea [117], and ageing
[167]. It has been a powerful research tool that has enhanced our
understanding of the atrial substrate in patients with paroxysmal
and persistent atrial fibrillation and [74,434] those who have failed
initial PV antrum isolation [435].
Unlike cardiac MR, CT, or echocardiography, EAM requires
invasive catheterization and mapping. However, despite recent
advances in MRI techniques that allow for imaging atrial scar, EAM
imaging arguably has a great clinical feasibility and superior ability
to image and to define the atrial substrate that leads to the
development of atrial fibrillation. A recent consensus report on
multi-modality imaging for AF patients is a useful detailed refer-
ence [346].
7.6. Ablation of atrial tachyarrhythmia
Numerous single-centre, randomized studies and larger mul-
ticentre observational registries have demonstrated the super-
iority of AF ablation over drug therapy for maintenance of sinus
rhythm. However, late recurrences are common and associated
with more advanced atrial substrate associated with structural
heart disease [436–446].
It is in this context that it is important to consider the various
types of underlying atrial cardiomyopathy and how they may
affect ablation outcomes. This is timely, as it has recently been
observed that lone AF is a rapidly disappearing entity as we
recognise conditions such as sleep apnoea, obesity, endurance
exercise etc. previously not suspected of being causally associated
with atrial fibrillation [447]. In addition, emerging data suggest
that treating these underlying causes may be central to improving
long-term ablation outcomes [199,200,448,449]. In addition, LA
ablation procedures may alter atrial size, structure, and mechan-
ical atrial function. Catheter ablation may thus influence ongoing
pathologies and atrial thrombogenesis [450,451].
Mapping studies have demonstrated a common electro-
physiological endpoint for a range of such conditions affecting the
atrium either primarily or secondarily, many of which have been
shown to be associated with atrial remodelling characterised by
conduction slowing and myocardial voltage reduction suggesting
fibrosis [117,167,177,433,452,453]. Magnetic resonance imaging
techniques attempting to characterize the extent of myocardial
fibrosis have demonstrated that this appears to be the strongest
independent predictor of AF recurrence after ablation [416,454].
Whether the EHRAS classification has value for informing catheter
ablation in human atria remains to be determined.
7.7. Age and atrial fibrillation ablation
Increasing age has been shown to be associated with increasing
atrial fibrosis in both basic and clinical studies [167,455]. Numer-
ous studies have evaluated ablation outcomes in ageing patients(variously defined as .65 through to .80) [444,445,456–462].
Observational studies have consistently reported high multiple
procedure success rates at 12 months of up to 80% in older
patients. Conflicting data exist regarding outcomes in comparative
studies with one study demonstrating a reduced success rate in
patients over 65 years while another study showed similar efficacy
in patients over the age of 80 years to the younger cohort
[461,463].
7.8. Hypertension
Hypertension is another well-recognised risk factor for devel-
opment of atrial fibrillation. Mapping studies have demonstrated
the presence of a more advanced atrial substrate in hypertensive
patients compared with controls [177,464]. Hypertension has been
shown to be a risk factor for recurrence of AF after AF ablation in
numerous studies on univariate analysis, but it is less clear whe-
ther this is independent of factors such as atrial size. Recent pre-
liminary studies have suggested that aggressive treatment of
hypertension improves post-ablation outcomes [200,464,465].
7.9. Heart failure and atrial fibrillation ablation
Contractile dysfunction has similarly been associated with
advanced atrial remodelling and predisposition to atrial fibrillation
both in basic and in clinical studies [113,433]. Numerous studies
have evaluated the efficacy of catheter ablation of both paroxysmal
and persistent atrial fibrillation with significant impairment of
systolic function [437,466–473]. The weight of evidence is that
sinus rhythm can be successfully achieved in 50–80% of patients
although repeat procedures are common and follow-up periods
are usually not more than 12 months. Successful ablation has been
associated with significant improvements in ejection fraction and
reduction in atrial size in the majority of studies [470,474].
7.10. Metabolic syndrome and obesity
A number of studies have evaluated the impact of the meta-
bolic syndrome on catheter ablation outcomes in atrial fibrillation
patients [475–480]. Although the data are mixed, the weight of
studies and a systematic review [477] suggest a higher risk of AF
recurrence. In the ARREST AF study, patients with BMI over 27
undergoing AF ablation had a much lower risk of recurrence if
weight loss was achieved and maintained [200]. Observational
studies have demonstrated a significantly lower risk of recurrent
AF in patients with treated compared with untreated OSA [481].
7.11. Impact of diabetes on ablation outcomes
Several studies have documented an increased recurrence rate
of atrial fibrillation after an ablation procedure in patients with
diabetes mellitus [204,475,482]. An abnormal atrial substrate and
non-PV triggers have been shown to underlie this worse outcome.
7.12. Role of myocarditis
Markers of inflammation such as CRP and IL-6 have been linked
to risk of AF [267,483–485]. Recently, giant-cell myocarditis
involving only the atria has been shown to result in atrial fibril-
lation with enlarged atria [149]. Patients with apparently lone
atrial fibrillation frequently demonstrate histological findings
consistent with an atrial myocarditis [486]; and those with past
myocarditis may have atrial electrical scar, conduction abnormal-
ities, or atrial standstill [146,487–489]. Baseline CRP levels have
been associated with the risk of recurrent AF after catheter abla-
tion [278]. Recently, colchicine has been used to prevent atrial
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that AF in itself can result in inflammation and the development of
an ‘atrial myocarditis’ [491].
7.13. Impact of atrial fibrillation duration on atrial myopathy and
atrial fibrillation ablation outcomes
Longitudinal studies in AF patients have demonstrated clinical
progression of AF over time in a significant proportion with risk
strongly associated with drivers such as increasing age, structural
heart disease, and hypertension [492]. Chronic AF results in
structural change with a recent study showing that in proportion
to AF burden, atrial remodelling may progress significantly even
over a time period as short as 1 year.
Numerous studies have demonstrated that atrial size and
occasionally mechanical function may improve following ablation
[493], but at least one invasive study showed no improvement in
atrial electrophysiology 6 months after successful ablation [219].
Overwhelmingly, studies evaluating long-term outcomes after
ablation of persistent atrial fibrillation have demonstrated lower
rates of procedural reversion to sinus rhythm and higher late
recurrence rates reflecting more advanced atrial substrate.
7.14. Impact of ongoing atrial fibrillation on electrical and structural
remodelling
It is now well known that in the presence of an appropriate
heterogenous AF substrate, a focal trigger can result in sustained
high-frequency re-entrant AF drivers, named rotors. The waves
that emerge from these rotors undergo spatially distributed frag-
mentation and so give rise to fibrillatory conduction. When high-
frequency atrial activation is maintained for at least 24 h, ion-
channel remodelling changes the electrophysiologic substrate,
promoting perpetuation of re-entry and increasing the activity of
triggers, further contributing to AF permanence [494]. Atrial
fibrillation itself leads to remodelling, causing electrophysiological
(electrical), contractile, and structural changes [495,496]. Although
AF can typically be reversed in its early stages, it becomes more
difficult to eliminate over time due to such remodelling [238,497].
Dominant-frequency analysis points to an evolution of mechan-
isms in AF patients, with PV sources becoming less predominant as
AF becomes more persistent and atrial remodelling progresses
[498]. The data suggest that in patients with long-standing per-
sistent AF, atrial remodelling augments the number of AF drivers
and shifts their location away from the PV/ostial region.
7.15. Impact of catheter ablation on atrial pathology
Several studies have examined LA size before and after catheter
ablation and have demonstrated a 10–20% decrease in the
dimensions of the LA after catheter ablation of AF [499,500].
Although the precise mechanism of this decrease in size is not
known, it appears consistent with reverse remodelling. It has been
suggested that earlier aggressive intervention to maintain sinus
rhythm, including AF ablation if needed, may aid to prevent
‘chronicization’ of AF and improve long-term outcomes [501]. A
large-scale multicentre trial is presently testing this idea [502].
The true impact of atrial cardiomyopathies on the success of
catheter ablation has not been elucidated. Nevertheless, it is very
likely that atrial pathology affects energy delivery to tissue and
specific forms of cardiomyopathy may differentially affect ablation
procedures. However, the true impact and interaction of various
energy sources with different atrial pathologies need to be studied.8. Conclusion
Atrial cardiomyopathies as defined in this consensus paper
have a significant impact on atrial function and arrhythmogenesis.
The EHRAS classification (EHRAS Class I–IV) is a first attempt to
characterize atrial pathologies into discrete cohorts. Because
disease-related histological changes in atrial tissue are often
poorly characterised, not necessarily specific and vary considerably
over time their classification is challenging. Further studies are
needed to implement and validate the EHRAS classification and to
assess its value in guiding clinical understanding and management
of AF. Nevertheless, a more precise, defined classification of atrial
pathologies may contribute to establishing an individualised
approach to AF therapy, which might improve therapeutic
outcomes.Supplementary material
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